Skip to content
Open access

Sequencing BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma: A Real-World Comparison of CAR T-Cell Therapy and Bispecific Antibodies

Sep 2026 · Cancers · Vol 18 · 0 citations · 52 references
Medicine

Abstract

Simple Summary B-cell maturation antigen (BCMA)-directed therapies (BDT) are approved for the treatment of relapsed/refractory multiple myeloma (RRMM). Several treatment modalities exist including chimeric antigen receptor T-cell therapy (CAR-T), bispecific antibodies (BsAbs), and antibody-drug conjugates (ADC). The effectiveness of BCMA-targeting CAR-T and BsAbs has not been compared directly in clinical trial so real-world data provides insight into relative effectiveness. We present retrospectively-collected data comparing CAR-T and BsAbs in patients with RRMM from major US academic institutions. We also explored the impact of prior BDT (BDT-exposed, versus BDT-naïve). CAR-T led to more durable responses in the BDT-naïve setting than BsAbs. Responses to either modality were weaker in the BDT-exposed setting. Furthermore, our data suggest that the washout period and the choice of first BDT impact response rates in the exposed setting. These results highlight the importance of sequencing BDT in RRMM.

Read PDF

Similar papers

Review Open access Oct 2026

BCMA-Targeted Immunotherapy in Early Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Practical Management.

BACKGROUND B-cell maturation antigen (BCMA), a plasma cell-restricted member of the tumor necrosis factor receptor superfamily, has emerged as the premier immunotherapeutic target in Multiple Myeloma (MM). METHODS We performed a comprehensive, comparative review of pivotal Phase II and III clinical trials of BCMA-dir...

Massimo Martino, Erica Bilardi, M. Pitea et al. · 0 citations
Open access Sep 2026

Real-World Efficacy and Safety of Standard-of-Care Chimeric Antigen Receptor T-Cell (CART) and Bispecific T-Cell Engager (TCE) Therapies in Relapsed/Refractory Multiple Myeloma (RRMM).

We aimed to evaluate the real-world (RW) efficacy and safety of standard-of-care CART versus TCE therapies in relapsed/refractory myeloma (RRMM), to assess utilization, outcomes, and tolerability of these therapies in a RW oncology in the US. Data were derived from the US-based, electronic health record-derived deident...

Poy Theprungsirikul, Rong Wang, Su-Hsin Chang et al. · 0 citations
Open access Oct 2026

Comparative effectiveness of CAR-T cell therapy and CD20xCD3 bispecific antibodies in relapsed/refractory follicular lymphoma: A propensity score–matched real-world analysis.

639 Background: CD20×CD3 bispecific antibodies and chimeric antigen receptor T-cell (CAR-T) therapy have expanded treatment options for relapsed/refractory follicular lymphoma (R/R FL). Although both therapies demonstrate substantial clinical activity, comparative real-world data remain limited. We compared sur...

Navya Pillikunte Doddareddy, Ranjit Sah, G. Sorescu · 0 citations
Review Open access Sep 2026

Sequencing CD19-targeted therapies in patients with relapsed/refractory large B-cell lymphoma: A narrative review.

The unmet needs in patients with high-risk disease and the challenges of sequencing these therapeutic strategies are discussed, while providing expert clinical practice recommendations to optimize patient outcomes are provided.

P. Caimi, Romano Danesi, G. Iacoboni et al. · 0 citations
Review Open access Oct 2026

T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis

Chimeric antigen receptor T cells and bispecific antibodies, are moving from late-line salvage into early relapsed multiple myeloma. Indirect comparisons in heavily pretreated patients have favored cell therapy, but whether that hierarchy holds in early relapse is unknown. We analyzed randomized phase 3 trials comparin...

Maximilian Merz, J. Souto, P. Voorhees et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.